Cinryze label expansion in USA boosts Shire stock

21 June 2018

In London, Takeda (TYO: 4502) takeover target Shire (LSE: SHP) jumped more than 2% in morning trading on Thursday, after the rare disease expert revealed US regulators had approved a potentially lucrative label expansion for Cinryze (C1 esterase inhibitor).

The drug, available since 2008, may now be marketed to help prevent angioedema attacks in children aged six years and older with hereditary angioedema (HAE). Previously it was labeled only for routine prophylaxis against attacks in adult and adolescent HAE patients.

The news will cheer Takeda chief executive Christophe Weber, who is struggling to convince a minority of recalcitrant board members of the wisdom of his firm’s $62 billion takeover offer, accepted by Shire in early May.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK